Q2 Conf. call brief summary - Press Release here
-
Singapore facility has been redundant, hence sold. 50 Cr. Ebita improvement each year.
-
Current Debt/Ebita 3.3 times, below 3 Debt/Ebita by year end. Debt reduction of 700 Cr. in H2 with Syngene transaction closing
-
Reduction in cash conversion cycle is in focus
-
Guidance for US revenue $250 Mn. for FY2024 will be achieved; In 2 next year, it should reach $400 Mn. with current margin profile. Avg. product size for future launch products to be about $15-20 Mn. vs $5-7 Mn. and new products launches expected in US. 3-4 products expected to be more than $20 Mn.
-
Focus on conversion from Ebita to free cash
-
Excited about second half of the year
-
$150-160 Mn, CDMO business next year FY25. CDMO revenue by FY27 expected to be $400 Mn.
-
Debt to Ebita next year to be much below 2; Focus on reduction of working capital days there by reducing working capital debt
-
Post US target revenue of $400 Mn achieved, the focus will be shifting to create similar revenue stream from other market (mirror US markets in terms of revenue and margin
Disc - Invested; Biased
Subscribe To Our Free Newsletter |